Breaking News
March 21, 2019 - Smell of skin could lead to early diagnosis for Parkinson’s
March 21, 2019 - Difference in brain connectivity may explain autism spectrum disorder
March 21, 2019 - Untangling the microbiome — with statistics
March 21, 2019 - Human microbiome metabolites enhance colon injury by enterohemorrhagic E. coli, study shows
March 21, 2019 - Written media can improve citizens’ understanding of palliative care
March 21, 2019 - New research aims to find how asthma symptoms are aggravated
March 21, 2019 - New $9.7 million NIH grant project seeks to improve hearing restoration
March 21, 2019 - Researchers measure brain metabolite levels in people with mild memory problems
March 21, 2019 - FDA approves first drug for treatment of postpartum depression in adult women
March 20, 2019 - Gene editing and designer babies experiments face global moratorium
March 20, 2019 - Major scientific study of wound care dressings wins ‘Best Clinical or Preclinical Research Award’
March 20, 2019 - Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
March 20, 2019 - Big data study identifies drugs that increase risk of psychosis in youth with ADHD
March 20, 2019 - Mystery novel and dream spur key scientific insight into heart defect | News Center
March 20, 2019 - Study measures impact of policies designed to reduce air pollution in two mega-cities
March 20, 2019 - Mild sleep apnea during pregnancy changes sugar levels and may affect infant growth patterns
March 20, 2019 - SSB and Novasep collaborate to develop new membrane chromatography systems
March 20, 2019 - Leaky valve repair improves quality of life in heart failure patients
March 20, 2019 - Diattenuation Imaging offers structural information of difficult to access brain regions
March 20, 2019 - Early sports specialization linked to increased injury rates during athletic career
March 20, 2019 - Study brings clarity about milk intake for children with Duarte galactosemia
March 20, 2019 - Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
March 20, 2019 - Maternal smoking during pregnancy increases risk of ADHD among offspring up to three-fold
March 20, 2019 - Pioneering pediatric kidney transplant surgeon Oscar Salvatierra dies at 83 | News Center
March 20, 2019 - F.D.A. Approves First Drug for Postpartum Depression
March 20, 2019 - TB remains a major public health challenge in the European region
March 20, 2019 - Most pills contain common allergens, warn experts
March 20, 2019 - Researchers discover previously unknown mechanism by which cells can sense oxygen
March 20, 2019 - World’s leading source of data on diagnosis, treatments for aortic dissection
March 20, 2019 - Breast cancer relapse predictor may soon be a reality
March 20, 2019 - Researchers identify origin of chronic pain in humans
March 20, 2019 - Two-drug combinations containing calcium channel blocker significantly lowers BP
March 20, 2019 - King’s scientists to monitor air quality exposure of 250 children
March 20, 2019 - Preventative cardioverter defibrillator implantation is of little benefit to kidney dialysis patients
March 20, 2019 - New method based on neurofeedback may reduce anxiety
March 20, 2019 - Study explores whether alcohol consumption can have an effect on arthritis
March 20, 2019 - Merck to collaborate with GenScript for plasmid and virus manufacturing in China
March 20, 2019 - FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression
March 20, 2019 - Study examines long-term opioid use in patients with severe osteoarthritis
March 20, 2019 - Retired Stanford professor Edward Rubenstein, pioneer in intensive care medicine, dies at 94 | News Center
March 20, 2019 - Aaron Diamond AIDS Research Center to Join Columbia University
March 20, 2019 - Call for halt to human gene editing and designer babies experiments
March 20, 2019 - Study illuminates how hot spots of genetic variation evolved in the human genome
March 20, 2019 - Roundworm study suggests alternatives for treatment of schizophrenia
March 20, 2019 - Sphingotec reports new applications of bio-ADM at 39th ISICEM
March 20, 2019 - Preventing falls through free community-based screenings for older adults
March 20, 2019 - AAOS: Supplement Use Low in Patients With Osteoporosis, Hip Fracture
March 20, 2019 - Does intensive blood pressure control reduce dementia?
March 20, 2019 - Nut consumption could be key to better cognitive health in older people
March 20, 2019 - Drinking hot tea associated with increased risk of esophageal cancer
March 20, 2019 - Androgen receptor plays vital role in regulating multiple mitochondrial processes
March 20, 2019 - NIH announces funding boost for Detroit Cardiovascular Training Program
March 20, 2019 - Study reveals another surgical option for patients with irreparable rotator cuff tears
March 20, 2019 - New robot-guided video game may be effective and low-cost solution for caregivers
March 20, 2019 - Heart Attacks Fall By One-Third Among Older Americans
March 20, 2019 - Data sharing uncovers five new risk genes for Alzheimer’s disease
March 20, 2019 - Does It Make Sense To Delay Children’s Vaccines?
March 20, 2019 - Lack of health insurance may increase Aging immigrants’ risk for cardiovascular disease
March 20, 2019 - Piece of puzzle unlocked in what drives alcohol addiction
March 20, 2019 - Researchers investigate whether Zika reservoirs are found in the Americas
March 20, 2019 - Compounds found in coffee may inhibit growth of prostate cancer
March 20, 2019 - Lab Innovations returns to the NEC on 30 & 31 October 2019
March 20, 2019 - How genes affect tobacco and alcohol use
March 20, 2019 - Osteoarthritis and rheumatoid arthritis have similar impacts on patients
March 20, 2019 - Individuals with infection history have higher risk of developing Sjögren’s syndrome
March 20, 2019 - Nursing home residents benefit from individualized multi-component exercise program
March 20, 2019 - Plant cellulose bone implants are “viable” option to support new bone growth, study finds
March 20, 2019 - Older people living in retirement communities benefit from improved health
March 20, 2019 - UTSA professor helps train first responders to detect prescription opioid overdoses
March 20, 2019 - Biohaven’s Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy
March 20, 2019 - Smoking may limit body’s ability to fight dangerous form of skin cancer
March 20, 2019 - Researchers receive $9.7-million grant to develop new hearing-loss treatments for deaf
March 20, 2019 - TGen and ABL sign agreement to distribute new TB test technology
March 20, 2019 - UCD researchers lead development of new urine test to detect prostate cancer
March 20, 2019 - Miniature brains that can move muscles, grown in the lab
March 20, 2019 - Servier and Oncodesign announce research and drug development partnership
March 20, 2019 - FDA warns marketer of unapproved products claiming to treat addiction, chronic pain
March 20, 2019 - TB Medicine Pretomanid Enters Regulatory Review Process in the United States
March 20, 2019 - Breastfeeding can erase effects of prenatal violence for newborns
March 20, 2019 - Tens of Thousands of Heart Patients May Not Need Open-Heart Surgery
Shorter treatment for Chagas disease found to be effective and safer than standard treatment

Shorter treatment for Chagas disease found to be effective and safer than standard treatment

image_pdfDownload PDFimage_print

A two-week treatment course for adult patients with chronic Chagas disease showed, when compared to placebo, similar efficacy and significantly fewer side effects than the standard treatment duration of eight weeks, according to the results of a clinical trial in Bolivia led by the Drugs for Neglected Diseases initiative (DNDi).

Chagas disease affects an estimated six million people globally and can lead to irreversible damage to vital organs, and death. Benznidazole, one of the two drugs used to treat Chagas, is traditionally administered twice a day over a course of eight weeks, in line with PAHO and WHO recommendations and national guidelines.

The Phase II clinical trial, carried out in three centres in Bolivia, sought to improve safety, tolerability and efficacy of treatment with this drug, which was discovered half a century ago. Initiated in 2016, it was the first-ever placebo-controlled study to test various lengths and dosages of treatment with benznidazole, both on its own as a monotherapy, and in combination with fosravuconazole.

The results were presented for the first time today at the “XV Jornada sobre la Enfermedad de Chagas”, organised by the Barcelona Institute for Global Health (ISGlobal, a centre supported by “la Caixa”). “We believe treatment can spare people with Chagas the risk of a lifetime of debilitating complications associated with the disease. However, the current treatment can cause severe side effects, which has often discouraged some people from seeking treatment and healthcare workers from recommending it,” said Joaquim Gascon, a principal investigator in the trial and the director of the Chagas Initiative at ISGlobal.

“We’ve shown that shorter treatment could be just as effective, and much safer. This could change the paradigm for Chagas treatment, by improving adherence and encouraging wider adoption by the medical community,” said Dr Faustino Torrico, President of CEADES Foundation, Bolivia, and a principal investigator in the trial.

All arms of the study, both monotherapy and combination, were shown to be efficacious. Eighty percent of the patients assigned to the group which took the standard dose of 300mg/day of benznidazole, but for two weeks instead of the standard eight weeks, showed no sign of the parasite in their blood six and 12 months after finishing the treatment. A similar result was observed in the group that took the standard eight-week treatment.

Significantly, none of those in the two-week reduced duration group interrupted treatment. On average, 2 in 10 patients who followed the standard course of treatment with benznidazole abandoned the treatment due to side effects.

“These results bring new hope for people living with this silent disease and could change the reality of access to treatment in endemic countries. With a much simpler treatment regimen, there is no excuse for not treating people with Chagas disease,” said Dr Sergio Sosa Estani, Head of Chagas Clinical Programme at DNDi. “DNDi will now continue to work with national programmes, partners and ministries of health of endemic countries to confirm these results and encourage necessary steps to register the new regimen and turn this breakthrough discovery into a reality for people affected by the disease.”

The trial was conducted in partnership with CEADES (Fundacion Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente), ISGlobal, Japanese pharmaceutical company and manufacturer of fosravuconazole Eisai Co. Ltd., Argentinian pharmaceutical company and manufacturer of benznidazole Elea, and associated non-profit foundation Fundación Mundo Sano, among others, and funded by the Global Health Innovative Technology Fund (GHIT).

DNDi continues to work on pre-clinical and clinical research to discover, develop, and test new drugs and drug combinations to treat Chagas.

Source:

https://www.isglobal.org/en/-/un-tratamiento-mas-corto-para-el-chagas-puede-ser-igual-de-eficaz-y-mucho-mas-seguro

Tagged with:

About author

Related Articles